IP Library Granted Patent US 12703748
Granted Patent B2
US 12703748 · App. 18/074,411 · Granted Aug 11, 2026

Anti-CD28 compositions

Inventors: John R. Desjarlais (Pasadena, CA); Gregory Moore (Azusa, CA); Michael Hedvat (Encino, CA); Juan Diaz (Anaheim Hills, CA); Veronica Gusti Zeng (Duarte, CA)
Assignee: Xencor, Inc.
C07K16/2827C07K16/2818C07K2317/31C07K2317/522C07K2317/524C07K2317/526C07K2317/53C07K2317/56C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703748
App. No.
18/074,411
Granted
Aug 11, 2026
Kind
B2
Abstract

Provided herein are novel anti-CD28 x anti-B7H3 (also referred to as “αCD28 x αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28 x αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.

Claims (16)

1 . A construct comprising a CD28 antigen binding domain (ABD), the CD28 binding domain comprising:

a) a variable heavy domain (VH) the amino acid sequence of SEQ ID NO:880, and b) a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.

2 . A nucleic acid composition comprising:

a) a first nucleic acid encoding a variable heavy domain (VH) having the amino acid sequence of SEQ ID NO:880; and

b) a second nucleic acid encoding a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.

3 . An expression vector composition comprising:

a) a first expression vector comprising a first nucleic acid encoding a variable heavy domain (VH) having the amino acid sequence of SEQ ID NO:880; and

b) a second expression vector comprising the second nucleic acid encoding a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.

4 . A host cell comprising the nucleic acid composition of claim 2 or the expression vector composition of claim 3 .

5 . A method of making a construct comprising culturing the host cell of claim 3 under conditions wherein the construct is expressed and recovering the composition.

6 . An antibody comprising a CD28 binding domain, wherein the CD28 binding domain comprises:

a) a variable heavy domain (VH) having the amino acid sequence of SEQ ID NO:880, and b) a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.

7 . A nucleic acid composition encoding the antibody of claim 6 .

8 . An expression vector composition comprising the nucleic acid composition of claim 7 .

9 . A host cell comprising the nucleic acid composition of claim 7 or the expression vector composition of claim 8 .

10 . A method of making an antibody comprising culturing the host cell of claim 9 under conditions wherein the antibody is expressed and recovering the antibody.